Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Experimental | 6 | 2021 | 94 | 2.650 |
Why?
|
| Nimodipine | 3 | 2023 | 3 | 2.390 |
Why?
|
| Dantrolene | 3 | 2023 | 3 | 1.730 |
Why?
|
| Vasospasm, Intracranial | 2 | 2021 | 16 | 1.490 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2012 | 27 | 1.410 |
Why?
|
| Cardiomyopathies | 4 | 2009 | 56 | 1.170 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2023 | 86 | 0.960 |
Why?
|
| Oxidative Stress | 3 | 2018 | 938 | 0.860 |
Why?
|
| Hemodynamics | 3 | 2011 | 91 | 0.780 |
Why?
|
| Angiotensin II | 4 | 2015 | 97 | 0.770 |
Why?
|
| Rats | 12 | 2023 | 3483 | 0.760 |
Why?
|
| Caffeine | 2 | 2018 | 28 | 0.740 |
Why?
|
| Serotonin | 3 | 2021 | 123 | 0.710 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 77 | 0.700 |
Why?
|
| Animals | 23 | 2023 | 15081 | 0.650 |
Why?
|
| Heart | 2 | 2014 | 180 | 0.640 |
Why?
|
| Blood Glucose | 3 | 2015 | 353 | 0.630 |
Why?
|
| Propanolamines | 2 | 2008 | 12 | 0.630 |
Why?
|
| Lactation | 1 | 2018 | 40 | 0.620 |
Why?
|
| Cricetinae | 9 | 2012 | 238 | 0.610 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2023 | 1618 | 0.610 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2008 | 52 | 0.610 |
Why?
|
| Cerebellum | 1 | 2018 | 73 | 0.610 |
Why?
|
| Vasoconstriction | 3 | 2006 | 42 | 0.610 |
Why?
|
| Cardiac Output | 7 | 2014 | 20 | 0.610 |
Why?
|
| Seizures | 1 | 2018 | 68 | 0.610 |
Why?
|
| Carbazoles | 2 | 2008 | 42 | 0.600 |
Why?
|
| Vasodilator Agents | 4 | 2019 | 56 | 0.580 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 12 | 0.550 |
Why?
|
| Coronary Vessels | 3 | 2006 | 85 | 0.540 |
Why?
|
| Simvastatin | 2 | 2014 | 29 | 0.540 |
Why?
|
| Pyrroles | 2 | 2014 | 55 | 0.530 |
Why?
|
| Mothers | 1 | 2018 | 181 | 0.530 |
Why?
|
| Gastric Bypass | 1 | 2015 | 17 | 0.520 |
Why?
|
| Renin-Angiotensin System | 4 | 2013 | 36 | 0.510 |
Why?
|
| Lipids | 2 | 2015 | 235 | 0.510 |
Why?
|
| Celiac Artery | 1 | 2015 | 1 | 0.510 |
Why?
|
| Motor Activity | 1 | 2018 | 418 | 0.500 |
Why?
|
| Resistance Training | 1 | 2015 | 18 | 0.500 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2021 | 130 | 0.500 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2012 | 37 | 0.490 |
Why?
|
| Male | 24 | 2021 | 20025 | 0.490 |
Why?
|
| Endothelium, Vascular | 4 | 2019 | 237 | 0.480 |
Why?
|
| Toremifene | 2 | 2003 | 4 | 0.470 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 101 | 0.460 |
Why?
|
| Estrogen Antagonists | 2 | 2003 | 28 | 0.460 |
Why?
|
| Ovariectomy | 2 | 2003 | 105 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 68 | 0.450 |
Why?
|
| Blood Pressure | 7 | 2015 | 646 | 0.450 |
Why?
|
| Hypertension | 3 | 2013 | 796 | 0.440 |
Why?
|
| Fumarates | 1 | 2012 | 11 | 0.420 |
Why?
|
| Renin | 1 | 2012 | 30 | 0.420 |
Why?
|
| Etomidate | 1 | 2011 | 1 | 0.410 |
Why?
|
| Mesocricetus | 5 | 2010 | 54 | 0.410 |
Why?
|
| Diabetes Complications | 2 | 2013 | 90 | 0.410 |
Why?
|
| Ketamine | 1 | 2011 | 11 | 0.400 |
Why?
|
| Propofol | 1 | 2011 | 8 | 0.400 |
Why?
|
| Amides | 1 | 2012 | 68 | 0.400 |
Why?
|
| Anesthetics | 1 | 2011 | 11 | 0.400 |
Why?
|
| Puerto Rico | 7 | 2015 | 1378 | 0.400 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 85 | 0.390 |
Why?
|
| Disease Models, Animal | 7 | 2012 | 1371 | 0.390 |
Why?
|
| Losartan | 2 | 2008 | 32 | 0.390 |
Why?
|
| Acetylcholine | 4 | 2019 | 73 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 69 | 0.380 |
Why?
|
| Time Factors | 5 | 2018 | 1742 | 0.370 |
Why?
|
| Aorta, Thoracic | 2 | 2010 | 28 | 0.370 |
Why?
|
| Acetylcysteine | 1 | 2010 | 62 | 0.360 |
Why?
|
| Coronary Circulation | 1 | 2009 | 27 | 0.350 |
Why?
|
| Antioxidants | 2 | 2010 | 416 | 0.350 |
Why?
|
| Heart Rate | 4 | 2014 | 253 | 0.340 |
Why?
|
| Potassium Chloride | 2 | 2006 | 28 | 0.340 |
Why?
|
| Exercise | 1 | 2015 | 613 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 643 | 0.330 |
Why?
|
| Enalapril | 1 | 2008 | 7 | 0.320 |
Why?
|
| Disease Progression | 5 | 2015 | 601 | 0.320 |
Why?
|
| Muscle Contraction | 3 | 2021 | 66 | 0.300 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 115 | 0.300 |
Why?
|
| Syncope | 1 | 2007 | 3 | 0.300 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 227 | 0.290 |
Why?
|
| Streptozocin | 2 | 2021 | 21 | 0.280 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 664 | 0.270 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 41 | 0.270 |
Why?
|
| Caregivers | 1 | 2008 | 182 | 0.270 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 96 | 0.260 |
Why?
|
| Nitric Oxide | 2 | 2005 | 316 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1039 | 0.250 |
Why?
|
| Stroke Volume | 3 | 2011 | 89 | 0.250 |
Why?
|
| Aging | 1 | 2009 | 664 | 0.240 |
Why?
|
| Doxorubicin | 1 | 2005 | 84 | 0.240 |
Why?
|
| Humans | 17 | 2021 | 37093 | 0.230 |
Why?
|
| Blood Vessels | 1 | 2003 | 34 | 0.230 |
Why?
|
| Cardiovascular System | 1 | 2003 | 33 | 0.220 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 70 | 0.220 |
Why?
|
| Reactive Oxygen Species | 1 | 2005 | 461 | 0.210 |
Why?
|
| Stress, Psychological | 1 | 2008 | 583 | 0.210 |
Why?
|
| Insulin Resistance | 2 | 2015 | 184 | 0.210 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 5 | 0.200 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 56 | 0.190 |
Why?
|
| Endothelin-1 | 2 | 2015 | 55 | 0.190 |
Why?
|
| Pravastatin | 2 | 2014 | 6 | 0.190 |
Why?
|
| Gambling | 1 | 2020 | 15 | 0.180 |
Why?
|
| Phenylephrine | 1 | 2019 | 36 | 0.180 |
Why?
|
| Receptor, Adenosine A2A | 2 | 2018 | 4 | 0.180 |
Why?
|
| Behavior, Addictive | 1 | 2020 | 32 | 0.170 |
Why?
|
| Self Efficacy | 1 | 2020 | 184 | 0.160 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 7 | 0.160 |
Why?
|
| Female | 9 | 2020 | 20969 | 0.160 |
Why?
|
| Cognition Disorders | 1 | 2020 | 233 | 0.150 |
Why?
|
| Gait | 1 | 2018 | 25 | 0.150 |
Why?
|
| Adenosine | 1 | 2018 | 59 | 0.150 |
Why?
|
| Fever | 1 | 2018 | 57 | 0.150 |
Why?
|
| Echocardiography | 2 | 2010 | 144 | 0.150 |
Why?
|
| Middle Aged | 7 | 2020 | 10129 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2026 | 0.140 |
Why?
|
| Adult | 6 | 2020 | 11712 | 0.140 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2008 | 31 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2008 | 67 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2015 | 27 | 0.130 |
Why?
|
| Swine | 2 | 2006 | 184 | 0.130 |
Why?
|
| Taurine | 1 | 2015 | 3 | 0.130 |
Why?
|
| Paullinia | 1 | 2015 | 3 | 0.130 |
Why?
|
| Spain | 2 | 2020 | 36 | 0.130 |
Why?
|
| Weight Loss | 1 | 2015 | 131 | 0.120 |
Why?
|
| Nitroprusside | 2 | 2003 | 15 | 0.120 |
Why?
|
| United States | 2 | 2015 | 4223 | 0.120 |
Why?
|
| Isometric Contraction | 2 | 2003 | 23 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 143 | 0.120 |
Why?
|
| Norepinephrine | 2 | 2003 | 110 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 142 | 0.110 |
Why?
|
| Heart Neoplasms | 1 | 2013 | 7 | 0.110 |
Why?
|
| Acid-Base Imbalance | 1 | 2013 | 3 | 0.110 |
Why?
|
| Body Weight | 1 | 2015 | 434 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2379 | 0.110 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 10 | 0.110 |
Why?
|
| Critical Illness | 1 | 2013 | 38 | 0.110 |
Why?
|
| Pregnancy | 1 | 2018 | 1549 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 148 | 0.110 |
Why?
|
| Diet, Mediterranean | 1 | 2013 | 40 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 50 | 0.110 |
Why?
|
| Valine | 1 | 2012 | 31 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2013 | 69 | 0.100 |
Why?
|
| Magnesium | 1 | 2013 | 97 | 0.100 |
Why?
|
| Incidence | 2 | 2013 | 922 | 0.100 |
Why?
|
| Tetrazoles | 1 | 2012 | 49 | 0.100 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 60 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 104 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2013 | 134 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2015 | 854 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 225 | 0.090 |
Why?
|
| Quinuclidines | 1 | 2009 | 5 | 0.090 |
Why?
|
| Tropanes | 1 | 2009 | 6 | 0.090 |
Why?
|
| Muscarinic Antagonists | 1 | 2009 | 12 | 0.090 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2009 | 34 | 0.090 |
Why?
|
| Aged | 5 | 2020 | 6741 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 628 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 602 | 0.080 |
Why?
|
| Acetamides | 1 | 2008 | 11 | 0.080 |
Why?
|
| Antiparkinson Agents | 1 | 2008 | 12 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2008 | 112 | 0.080 |
Why?
|
| Superoxides | 1 | 2008 | 53 | 0.080 |
Why?
|
| Inflammation | 1 | 2013 | 618 | 0.080 |
Why?
|
| Heart Failure | 1 | 2010 | 235 | 0.080 |
Why?
|
| Age Factors | 1 | 2010 | 1033 | 0.070 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 37 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2008 | 1369 | 0.070 |
Why?
|
| Vasodilation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2008 | 118 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1067 | 0.070 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 5 | 0.070 |
Why?
|
| Ketanserin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2006 | 3 | 0.070 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2006 | 5 | 0.070 |
Why?
|
| Propranolol | 1 | 2006 | 18 | 0.070 |
Why?
|
| Receptor, Endothelin A | 1 | 2006 | 3 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 2006 | 23 | 0.070 |
Why?
|
| Lovastatin | 1 | 2006 | 10 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2006 | 23 | 0.070 |
Why?
|
| Binding, Competitive | 1 | 2006 | 111 | 0.070 |
Why?
|
| Peptides, Cyclic | 1 | 2006 | 29 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 385 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 78 | 0.060 |
Why?
|
| Rats, Inbred SHR | 1 | 2005 | 32 | 0.060 |
Why?
|
| Systole | 1 | 2005 | 61 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 95 | 0.060 |
Why?
|
| Risk Factors | 1 | 2013 | 3562 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 134 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 191 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2005 | 163 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 19 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 204 | 0.060 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 36 | 0.060 |
Why?
|
| Hormones | 1 | 2003 | 55 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2003 | 9 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 128 | 0.050 |
Why?
|
| Aorta | 1 | 2003 | 167 | 0.050 |
Why?
|
| Protein Binding | 1 | 2006 | 972 | 0.050 |
Why?
|
| Myocardium | 1 | 2005 | 235 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 262 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 712 | 0.050 |
Why?
|
| Anxiety | 1 | 2008 | 754 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 284 | 0.050 |
Why?
|
| Reward | 1 | 2020 | 79 | 0.040 |
Why?
|
| Radioligand Assay | 2 | 2009 | 66 | 0.040 |
Why?
|
| Cricetulus | 2 | 2009 | 80 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2009 | 409 | 0.040 |
Why?
|
| Infant | 2 | 2013 | 1046 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4268 | 0.040 |
Why?
|
| Cognition | 1 | 2020 | 398 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2005 | 1908 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 5363 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 1418 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2013 | 11 | 0.030 |
Why?
|
| Critical Care | 1 | 2013 | 41 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 47 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2013 | 59 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2013 | 156 | 0.030 |
Why?
|
| Child | 2 | 2013 | 3131 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 169 | 0.020 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Bronchial Spasm | 1 | 2009 | 3 | 0.020 |
Why?
|
| Esters | 1 | 2009 | 28 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2009 | 80 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2009 | 145 | 0.020 |
Why?
|
| CHO Cells | 1 | 2009 | 124 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 167 | 0.020 |
Why?
|
| Drug Stability | 1 | 2009 | 116 | 0.020 |
Why?
|
| Catalepsy | 1 | 2008 | 8 | 0.020 |
Why?
|
| Haloperidol | 1 | 2008 | 26 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 118 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2008 | 70 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 143 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 233 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 325 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 149 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2006 | 5 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2006 | 90 | 0.020 |
Why?
|
| Water | 1 | 2008 | 296 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 1354 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 5913 | 0.010 |
Why?
|